Impact of cardiologist intervention on guideline-directed use of statin therapy

Table 1 Patient Clinic demographics, n = 268, n (%)

Patient characteristics	Data
Age (yr), mean	56 (± 10.65, SD)
Sex
Male	118 (44)
Female	150 (56)
Race
White	180 (67.2)
Black	60 (22.2)
Other	28 (10.4)
Ethnicity
Hispanic/Latin-o,-a	151 (56.3)
Smoker
Never	184 (68.7)
Former	48 (17.9)
Current	34 (12.7)
Unknown	2 (0.7)
ASCVD	38 (14.2)
mean ASCVD score	12.1%
Diabetes	177 (66)
Hypertension	171 (63.8)
Statin prescribed	149 (55)
Low	11 (4.1)
Moderate	82 (30.6)
High	56 (20.9)
Clinical laboratory profile
TC (mg/dL), mean	200.63 (46.7, SD)
LDL-C (mg/dL), mean	121.08 (36.9, SD)
HDL-C (mg/dL), mean	51.17 (15.2, SD)
SBP (mmHg), mean	132 (19.2, SD)

TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; SBP: Systolic blood pressure.

Table 2 Adherence to guideline-directed statin therapy and patient characteristics by group, n (%)

All patients (n = 268)	IMC only (n = 211)	IMC/CC (n = 57)	P value
Statin prescribed	107 (50.7)	42 (73)	0.002
Appropriate intensity statin prescribed	117 (55.5)	35 (61.4)	0.421
Distribution of population
Age(years), mean	55.47 (± 10.11, SD)	62.14 (± 11.08, SD)	< 0.001
ASCVD	18(8.5)	20 (35.1)	< 0.001
DM	64 (30.3)	27 (47.3)	0.016
Hypertension	125(59.2)	46 (80.70)	0.003
Smoking history (current and former)	55 (26.1)	27 (47.4)	0.002
Non-white	62 (29.4)	26 (45.6)	0.021
Hispanic, Latino	127 (60.2)	24 (42.1)	0.015
LDL-C (mg/dL), mean	123.98 (± 34.77, SD)	110.36 (± 42.47, SD)	0.013
TC (mg/dL), mean	204.13 (± 44.96, SD)	187.67 (± 50.77, SD)	0.018
HDL-C (mg/dL), mean	50.4 (± 14.1, SD)	53.9 (± 18.6, SD)	0.126

IMC: Internal Medicine Clinic; CC: Cardiology Clinic; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; SBP: Systolic blood pressure.